Despite biotech's struggles, quality and global diversification create opportunities in select names. Read why portfolio ...

It is vital for biotech companies to run the right clinical trial and not cut costs with trial design or patient recruitment, ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

BeiGene aims to be a next-generation oncology innovator by broadening its drug and pipeline portfolio to various solid tumors in addition to blood cancers. As such, it been actively investing to build ...

With growing uncertainty in the US, Chinese companies are swooping in to present themselves as stable, open partners to the Swiss biotech sector.

Post patent expiry, numerous Indian companies launched generic versions of Empagliflozin. The market witnessed a surge in ...

Colorado’s life sciences sector is growing, but leaders warn federal delays, housing costs and demographic shifts could ...

Biogen will open a West Coast hub in South San Francisco after acquiring a Peninsula drugmaker. HI-Bio's operations have ...

As it pieces together a $1 billion factory in Chesterfield, the Danish toymaker has another sizable build in the works in a ...

President Trump and Republicans appear to be shrinking from reforming Medicaid, but that’s not the worst of it. To replace ...

Donald Trump has promised to create a pro-AI environment, but even tech companies are frustrated by federal cuts that hamper regulatory processes. Paul Webster reports.